Aspirin Use is Associated With Lower Risk of Barrett's Esophagus in Women. Issue 12 (December 2017)

• Record Type: Journal Article
• Authors: Jovani, Manol; Cao, Yin; Feskanich, Diane; Drew, David A; Hur, Chin; Fuchs, Charles S; Jacobson, Brian C; Chan, Andrew T
• Is Part Of: Clinical and translational gastroenterology. Volume 8:Issue 12(2017)
• Publication Date: 2017-12
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology; Gastrointestinal Diseases; Liver Diseases; Intestines -- Diseases; Stomach -- Diseases; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals; 616.33
• DOI: 10.1038/ctg.2017.57
• Languages: English
• ISSNs: 2155-384X

Abstract

Abstract : OBJECTIVES: : Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma. Data examining the association of aspirin with the onset of BE, particularly for women, are scant and conflicting. METHODS: : We leveraged data from 121, 700 women enrolled in the Nurses' Health Study, a large prospective cohort study, who biennially provided detailed information regarding endoscopy and use of aspirin. We used unconditional logistic regression to obtain multivariable (MV)‐adjusted odds ratios (ORs) and 95% confidence intervals (CI) to estimate the risk of BE in regular aspirin users (≥2 times/week) compared to non‐regular users. RESULTS: : Among 27, 881 women who had undergone upper GI endoscopy, we documented 667 BE cases over 18 years of follow‐up. Compared to non‐regular users, women who regularly used aspirin had a MV‐adjusted OR for BE of 0.85 (95%CI: 0.72, 0.99). The corresponding OR was 0.73 (95%CI: 0.56, 0.96) for BE at least 1 cm long. Compared with women who did not use any aspirin, the MV‐adjusted OR for any BE was 0.91 (95% CI, 0.69, 1.20) for women taking 0.5‐1.5 tablets/week; 0.92 (95%CI 0.76, 1.11) for 2–5 tablets/week; and 0.71 (95%CI 0.55, 0.92) for ≥6 tablets/week (p‐trend=0.01). Compared with non‐regular users, the MV‐adjusted OR for BE risk was 0.90 (95%CI 0.67, 1.20) for women who regularly used aspirin for 1–5 years, 0.84 (95%CI 0.65, 1.09) for 6–10 years, and 0.81 (95%CI 0.67, 0.97) for >10 years (p‐trend=0.03). CONCLUSION: : Regular aspirin use was associated with a reduction in the risk of Barrett's esophagus in women. The reduction in risk appeared related to higher dose and longer duration of use.